Cargando…

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report

BACKGROUND: Collecting duct carcinoma and sarcomatoid renal cell carcinoma are tumors with poor prognosis. Immune checkpoint inhibitors have been established as the standard treatment for advanced renal cell carcinoma. Some cases of remission of collecting duct carcinoma and sarcomatoid renal cell c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuu, Takayoshi, Iijima, Kazuyoshi, Kusama, Yukiko, Otsuki, Toshiaki, Kato, Haruaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116048/ https://www.ncbi.nlm.nih.gov/pubmed/35581611 http://dx.doi.org/10.1186/s13256-022-03426-3

Ejemplares similares

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
por: Funajima, Keisuke, et al.
Publicado: (2023)

Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature
por: Hino, Christopher, et al.
Publicado: (2022)

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
por: Tomioka, Masayuki, et al.
Publicado: (2021)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
por: Sadagopan, Narayanan, et al.
Publicado: (2019)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
por: Peak, Taylor C., et al.
Publicado: (2020)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report
por: Yasuoka, Shotaro, et al.
Publicado: (2018)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2020)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
por: Segawa, Takuya, et al.
Publicado: (2023)

Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
por: Di Napoli, Marilena, et al.
Publicado: (2022)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
por: Furudate, Sadanori, et al.
Publicado: (2016)

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2022)

Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study
por: Chen, Yaolin, et al.
Publicado: (2021)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
por: Guercio, Brendan John, et al.
Publicado: (2021)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
por: Fuchizawa, Hirotaka, et al.
Publicado: (2021)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Savarapu, Pramod, et al.
Publicado: (2021)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report
por: Delombaerde, Danielle, et al.
Publicado: (2022)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
por: Vázquez-Montero, Lucía, et al.
Publicado: (2023)

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab
por: Hayashida, Michikata, et al.
Publicado: (2022)

A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma
por: Kijima, Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3egi3md492btvn718ja03utq0v